Literature DB >> 22193627

Targeting 14-3-3zeta in cancer therapy.

X Yang1, W Cao, L Zhang, W Zhang, X Zhang, H Lin.   

Abstract

An effective therapeutic target is imperative for cancer treatment, including gene therapy. 14-3-3zeta, a member of the 14-3-3 protein family, acts as a suppressor of apoptosis and has a central role in tumor genesis and progression. Owing to its wide upregulation in human tumors and its involvement in cancer progression and treatment resistance, 14-3-3zeta is currently undergoing extensive investigation as a novel therapeutic target. In this review, we widely investigate the role of 14-3-3zeta in cancer and suggest a potential therapeutic target for new anticancer interventions.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22193627     DOI： 10.1038/cgt.2011.85

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  19 in total

1.  Roles of vimentin and 14-3-3 zeta/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis.

Authors:  Yan Pan; Li-jun Zhong; Hong Zhou; Xin Wang; Kui Chen; Hao-peng Yang; Yilixiati Xiaokaiti; Aikebaier Maimaiti; Ling Jiang; Xue-jun Li
Journal:  Acta Pharmacol Sin       Date:  2012-06       Impact factor: 6.150

2.  Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.

Authors:  Yujia Wang; Lushuang Xu; Yang Liu; Yuzhe Hu; Qiang Shi; Lixue Jin; Lijun Yang; Pingzhang Wang; Kunshan Zhang; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

3.  Metabolic-stress-induced rearrangement of the 14-3-3ζ interactome promotes autophagy via a ULK1- and AMPK-regulated 14-3-3ζ interaction with phosphorylated Atg9.

Authors:  Vajira K Weerasekara; David J Panek; David G Broadbent; Jeffrey B Mortenson; Andrew D Mathis; Gideon N Logan; John T Prince; David M Thomson; J Will Thompson; Joshua L Andersen
Journal:  Mol Cell Biol       Date:  2014-09-29       Impact factor: 4.272

4.  14-3-3ζ regulates immune response through Stat3 signaling in oral squamous cell carcinoma.

Authors:  Xinguang Han; Yongfu Han; Huifeng Jiao; Yaqiong Jie
Journal:  Mol Cells       Date:  2014-12-30       Impact factor: 5.034

5.  Histone deacetylase 6 (HDAC6) promotes the pro-survival activity of 14-3-3ζ via deacetylation of lysines within the 14-3-3ζ binding pocket.

Authors:  Jeffrey B Mortenson; Lisa N Heppler; Courtney J Banks; Vajira K Weerasekara; Matthew D Whited; Stephen R Piccolo; William E Johnson; J Will Thompson; Joshua L Andersen
Journal:  J Biol Chem       Date:  2015-03-13       Impact factor: 5.157

6.  ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.

Authors:  D M Kambach; V L Sodi; P I Lelkes; J Azizkhan-Clifford; M J Reginato
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

7.  Establishing a novel knock-in mouse line for studying neuronal cytoplasmic dynein under normal and pathologic conditions.

Authors:  Jun Zhang; Alison E Twelvetrees; Jacob E Lazarus; Kiev R Blasier; Xuanli Yao; Nirja A Inamdar; Erika L F Holzbaur; K Kevin Pfister; Xin Xiang
Journal:  Cytoskeleton (Hoboken)       Date:  2013-03-21

8.  miR-451 regulates FoxO3 nuclear accumulation through Ywhaz in human colorectal cancer.

Authors:  Yaoyao Li; Jijun Wang; Xiaorong Dai; Zhengbin Zhou; Jing Liu; Yu Zhang; Yan Li; Yaying Hou; Lei Pang; Xiaohong Wang; Chenhai Wang; Zhenfeng Hao; Yanqing Zhang; Jixin Jiang; Hongwei Cheng; Duonan Yu
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

9.  Overexpression of 14-3-3ζ in lung tissue predicts an improved outcome in patients with lung adenocarcinoma.

Authors:  Man Li; Hailing Lu; Xiaolian Liu; Qingwei Meng; Yanbin Zhao; Xuesong Chen; Jing Hu; Wei Liu; Li Cai
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

10.  Down-regulation of 14-3-3zeta reduces proliferation and increases apoptosis in human glioblastoma.

Authors:  Xiaoliang Yang; Weidong Cao; Xiaofeng Wang; Xiang Zhang; Wei Zhang; Zenggang Li; Haian Fu
Journal:  Cancer Gene Ther       Date:  2019-05-09       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.